



Ohio Legislative Service Commission

Final Analysis

Audra Tidball

Am. H.B. 434

131st General Assembly
(As Passed by the General Assembly)

Reps. Baker, Blessing, Boccieri, M. O'Brien, Sprague, Antonio, Bishoff, Brown, Lepore-Hagan, Ramos, Anielski, Ashford, Barnes, Boyce, Boyd, Buchy, Celebrezze, Craig, Fedor, Hall, G. Johnson, T. Johnson, Landis, Leland, S. O'Brien, Pelanda, Rogers, Schaffer, Strahorn, Sweeney, Sykes, Rosenberger

Sens. Manning, Beagle, Tavares, Brown, Coley, Eklund, Faber, Gardner, Hackett, Hite, Hughes, Jones, Lehner, Obhof, Patton, Skindell, Thomas, Uecker, Yuko

Effective date: September 28, 2016

ACT SUMMARY

- Designates May as "Fibromuscular Dysplasia Awareness Month."

CONTENT AND OPERATION

The act designates May as "Fibromuscular Dysplasia Awareness Month."¹

Fibromuscular dysplasia is the abnormal development or growth of cells in the walls of the arteries, causing them to narrow or bulge. The alternating narrowing and enlarging of the arteries can block or reduce blood flow to the brain, resulting in a stroke or mini-stroke.

Some patients do not experience any symptoms of fibromuscular dysplasia, while others may have high blood pressure, dizziness or vertigo, chronic headache, intracranial aneurysm, ringing in the ears, weakness or numbness in the face, neck pain,

* This version updates the effective date.

¹ R.C. 5.232.

or changes in vision. Patients with minimal narrowing may be treated with blood thinners. Further treatment may include angioplasty, stents, and surgery.²

HISTORY

ACTION	DATE
Introduced	01-26-16
Reported, H. Health & Aging	02-24-16
Passed House (93-0)	04-13-16
Reported, S. Health & Human Services	05-18-16
Passed Senate (33-0)	05-24-16

16-HB434-UPDATED-131.docx/ks

² National Institutes of Health, National Institute of Neurological Disorders and Stroke, *NINDS Fibromuscular Dysplasia Information Page*, available at www.ninds.nih.gov/disorders/fibromuscular_dysplasia/fibromuscular_dysplasia.htm.

